Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.96 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | 10.92 | 55.63 | 9.56 | 10.85 | 2.71 | 3.57 | 7.73 | 8.92 | 25.30 | 23.03 | — | — | — | — |
| — | — | — | — | — | — | — | +303.1% | +1459.0% | +23.7% | +21.6% | -89.3% | -84.5% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.36 | 5.67 | 6.26 | 4.61 | 3.93 | 4.32 | 3.39 | 3.34 | 7.37 | 13.20 | 11.55 | 5.79 | — | 44.34 | 17.17 | 8.24 | 9.50 | 4.53 | 3.38 | 2.26 | 2.53 |
| — | +31.0% | +84.6% | +38.0% | -46.7% | -67.3% | -70.6% | -42.3% | — | -70.2% | -32.7% | -29.7% | — | +878.3% | +407.9% | +265.3% | +276.0% | +29.0% | +18.2% | -9.0% | -26.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 7.09 | — | — | — | 0.89 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +697.5% | — | — | — | — | — | — | |
| EV / EBITDA | — | 1.45 | — | 0.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | -30.8% | -422.1% | -214.9% | -126.2% | 17.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — |
| — | — | — | — | — | — | — | -273.1% | -522.1% | -314.9% | -226.2% | -82.2% | 0.0% | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | -69.2% | -575.2% | -291.9% | -209.2% | -10.6% | -111.0% | -197.8% | -274.0% | -840.3% | -407.0% | — | — | — | — |
| — | — | — | — | — | — | — | -552.5% | -418.4% | -47.6% | +23.7% | +98.7% | +72.7% | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | -63.9% | -555.2% | -277.0% | -199.6% | -6.3% | -103.3% | -188.0% | -260.1% | -804.3% | -400.3% | — | — | — | — |
| — | — | — | — | — | — | — | -914.2% | -437.4% | -47.3% | +23.3% | +99.2% | +74.2% | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -46.6% | -15.5% | -11.6% | -15.5% | -26.0% | -22.3% | -17.9% | -6.7% | -31.5% | -73.5% | -47.7% | -7.3% | -1354.6% | -164.8% | -86.4% | -56.7% | -37.3% | -32.8% | -27.9% | -18.2% | -11.2% |
| — | +30.3% | +35.0% | -132.5% | +17.3% | +69.7% | +62.6% | +9.1% | +97.7% | +55.4% | +44.7% | +87.1% | -3531.1% | -402.8% | -209.3% | -212.1% | -232.6% | -140.8% | -75.0% | -27.5% | +11.0% | |
| ROA | -39.9% | -11.7% | -10.0% | -12.5% | -18.9% | -18.0% | -15.0% | -5.4% | -19.1% | -25.1% | -18.1% | -1.6% | -15.4% | -14.8% | -14.9% | -14.8% | -11.4% | -11.6% | -14.7% | -14.7% | -9.5% |
| — | +35.0% | +33.9% | -131.5% | +1.2% | +28.1% | +16.9% | -239.9% | -24.5% | -70.0% | -21.2% | +89.3% | -35.1% | -27.6% | -1.6% | -1.2% | -20.1% | -1.6% | -11.6% | -24.3% | +11.2% | |
| ROIC | -92.8% | -12.6% | -24.0% | -37.0% | -23.4% | -21.9% | -15.5% | -8.0% | -178.4% | -73.5% | -49.5% | -37.2% | — | — | -448.6% | -83.2% | -65.4% | — | — | — | — |
| — | +42.5% | -55.0% | -361.3% | +86.9% | +70.2% | +68.8% | +78.5% | — | — | +89.0% | +55.2% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.37 | 0.08 | 0.06 | 0.21 | 0.04 | 0.04 | 0.03 | 0.07 | 0.45 | 0.29 | 0.25 | — | 0.81 | 0.39 | 0.22 | 0.18 | 0.15 | 0.11 | 0.09 | — |
| — | +778.2% | +109.2% | +76.8% | +190.3% | -90.7% | -87.6% | -86.6% | — | -44.4% | -24.1% | +14.3% | — | +457.3% | +238.8% | +137.4% | — | — | +985.7% | +711.1% | — | |
| Debt / EBITDA | — | 0.36 | — | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.01 | 7.35 | 8.42 | 9.01 | 3.59 | 4.37 | 6.55 | 7.77 | 4.19 | 1.37 | 1.57 | 1.63 | 0.90 | 1.11 | 1.25 | 1.82 | 2.05 | 2.69 | 4.16 | 8.82 | 13.82 |
| — | +68.1% | +28.5% | +16.0% | -14.4% | +218.6% | +317.1% | +377.8% | +367.4% | +23.9% | +25.1% | -10.6% | -56.2% | -58.9% | -69.9% | -79.4% | -85.2% | -77.9% | -63.3% | -22.2% | -11.3% | |
| Quick Ratio | 9.01 | 7.35 | 8.42 | 9.01 | 3.59 | 4.37 | 6.55 | 7.77 | 4.19 | 1.37 | 1.57 | 1.63 | 0.90 | 1.11 | 1.25 | 1.82 | 2.05 | 2.69 | 4.16 | 8.82 | 13.82 |
| — | +68.1% | +28.5% | +16.0% | -14.4% | +218.6% | +317.1% | +377.8% | +367.4% | +23.9% | +25.1% | -10.6% | -56.2% | -58.9% | -69.9% | -79.4% | -85.2% | -77.9% | -63.3% | -22.2% | -11.3% | |
| Interest Coverage | -33.49 | — | — | -8.91 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CAPR stock.
Capricor Therapeutics, Inc.'s current P/E is -4.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Capricor Therapeutics, Inc.'s business trajectory between earnings reports.